- Document Number:
20240082195
- Appl. No:
18/371085
- Application Filed:
September 21, 2023
- نبذة مختصرة :
The disclosure provides compositions comprising amino acids, individually and in combination, and methods of making the compositions and methods of using the compositions as pharmaceutically active agents to, inter alia, treat disease in animals, including humans.
- Claim:
1-20. (canceled)
- Claim:
21. A method of treating or preventing a methicillin-resistant Staphylococcus aureus infection in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising L-cysteine, L-glutamic acid, and L-aspartic acid, thereby treating or preventing the methicillin-resistant Staphylococcus aureus infection.
- Claim:
22. The method of claim 21 for treating the methicillin-resistant Staphylococcus aureus infection.
- Claim:
23. The method of claim 21, wherein the pharmaceutical composition comprises from about 0.1% (w/v) to about 5.0% (w/v) of L-cysteine, from about 0.1% (w/v) to about 5.0% (w/v) of L-glutamic acid, and from about 0.1% (w/v) to about 5.0% (w/v) of L-aspartic acid.
- Claim:
24. The method of claim 21, wherein the pharmaceutical composition comprises from about 0.1% (w/v) to about 1% (w/v) of L-cysteine, from about 0.1% (w/v) to about 1% (w/v) of L-glutamic acid, and from about 0.1% (w/v) to about 1% (w/v) of L-aspartic acid.
- Claim:
25. The method of claim 21, wherein the pharmaceutical composition is a liquid solution.
- Claim:
26. The method of claim 21, comprising topically administering the pharmaceutical composition.
- Claim:
27. The method of claim 21, comprising intravenously administering the pharmaceutical composition.
- Claim:
28. A method of treating or preventing a Staphylococcus infection in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising L-cysteine, L-glutamic acid, and L-aspartic acid, thereby treating or preventing the Staphylococcus infection.
- Claim:
29. The method of claim 28 for treating the Staphylococcus infection.
- Claim:
30. The method of claim 28, wherein the Staphylococcus infection is a Staphylococcus aureus infection.
- Claim:
31. The method of claim 28, wherein the Staphylococcus infection is a Staphylococcus epidermidis infection.
- Claim:
32. The method of claim 28, wherein the pharmaceutical composition comprises from about 0.1% (w/v) to about 5.0% (w/v) of L-cysteine, from about 0.1% (w/v) to about 5.0% (w/v) of L-glutamic acid, and from about 0.1% (w/v) to about 5.0% (w/v) of L-aspartic acid.
- Claim:
33. The method of claim 28, wherein the pharmaceutical composition comprises from about 0.1% (w/v) to about 1% (w/v) of L-cysteine, from about 0.1% (w/v) to about 1% (w/v) of L-glutamic acid, and from about 0.1% (w/v) to about 1% (w/v) of L-aspartic acid.
- Claim:
34. The method of claim 28, wherein the pharmaceutical composition is a liquid solution.
- Claim:
35. The method of claim 28, comprising topically or intravenously administering the pharmaceutical composition.
- Claim:
36. A method of treating or preventing an infection in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising L-cysteine, L-glutamic acid, and L-aspartic acid; wherein the infection is an Enterococcus faecalis infection, a Rothia dentocariosa infection, a Streptococcus infection, or a Stomatoccus mucilaginosus infection.
- Claim:
37. The method of claim 36, wherein the pharmaceutical composition comprises from about 0.1% (w/v) to about 5.0% (w/v) of L-cysteine, from about 0.1% (w/v) to about 5.0% (w/v) of L-glutamic acid, and from about 0.1% (w/v) to about 5.0% (w/v) of L-aspartic acid.
- Claim:
38. The method of claim 36, wherein the pharmaceutical composition comprises from about 0.1% (w/v) to about 1% (w/v) of L-cysteine, from about 0.1% (w/v) to about 1% (w/v) of L-glutamic acid, and from about 0.1% (w/v) to about 1% (w/v) of L-aspartic acid.
- Claim:
39. The method of claim 36, comprising topically or intravenously administering the pharmaceutical composition.
- Claim:
40. The method of claim 36, wherein the Streptococcus infection is a Streptococcus mitis infection, a Streptococcus salivarius infection, or a Streptococcus sobrinus infection.
- Current International Class:
61; 61; 61; 61; 61; 61; 61; 61; 61
- الرقم المعرف:
edspap.20240082195
Processing Request
No Comments.